AbbVie Inc. $ABBV Shares Purchased by Sanders Morris Harris LLC

Sanders Morris Harris LLC increased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 648.8% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 21,512 shares of the company’s stock after acquiring an additional 18,639 shares during the quarter. AbbVie makes up about 0.7% of Sanders Morris Harris LLC’s investment portfolio, making the stock its 24th largest position. Sanders Morris Harris LLC’s holdings in AbbVie were worth $4,981,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the stock. Marshall & Sullivan Inc. WA acquired a new position in shares of AbbVie during the 2nd quarter valued at about $25,000. Evolution Wealth Management Inc. acquired a new position in AbbVie in the 2nd quarter valued at about $26,000. TD Capital Management LLC grew its stake in shares of AbbVie by 82.9% in the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after buying an additional 58 shares during the period. Spurstone Advisory Services LLC acquired a new stake in shares of AbbVie during the 2nd quarter worth approximately $28,000. Finally, Financial Gravity Companies Inc. acquired a new position in AbbVie in the second quarter valued at approximately $36,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ABBV. Raymond James Financial set a $256.00 price target on AbbVie in a report on Monday, November 3rd. JPMorgan Chase & Co. lifted their price target on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, November 3rd. Guggenheim upped their price objective on shares of AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a report on Monday, October 20th. Piper Sandler reiterated an “overweight” rating and issued a $289.00 target price (up previously from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Finally, Berenberg Bank upgraded AbbVie from a “hold” rating to a “buy” rating and upped their price target for the stock from $170.00 to $270.00 in a research note on Wednesday, September 17th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $245.84.

AbbVie Stock Down 1.6%

AbbVie stock opened at $223.73 on Wednesday. The firm has a market capitalization of $395.43 billion, a P/E ratio of 169.50, a P/E/G ratio of 1.24 and a beta of 0.36. The company has a current ratio of 0.72, a quick ratio of 0.60 and a debt-to-equity ratio of 44.14. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The stock’s fifty day simple moving average is $227.00 and its 200-day simple moving average is $210.51.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. The firm had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.AbbVie’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same period in the previous year, the firm posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a yield of 3.1%. AbbVie’s dividend payout ratio (DPR) is presently 496.97%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.